[{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AT-1501","moa":"CD40 ligand","graph1":"Nephrology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AT-1501","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AT-1501","moa":"CD40 ligand","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AT-1501","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AT-1501","moa":"CD40 ligand","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Private Placement","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Neurology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0.19,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.19,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ BVF Partners","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ BVF Partners"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Endocrinology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Nephrology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Private Placement","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Leerink Partners"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"CareDx","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ CareDx","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ CareDx"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Nephrology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"eGenesis","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Immunology","graph2":"Preclinical","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Eledon Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Eledon Pharmaceuticals \/ Eledon Pharmaceuticals"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Neurology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Neurology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Nephrology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ BVF Partners","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ BVF Partners"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Endocrinology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"CareDx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Eledon Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Eledon Pharmaceuticals \/ Eledon Pharmaceuticals"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Sernova","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2025","type":"Agreement","leadProduct":"Human Donor Islet Cell","moa":"||Insulin hormone","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Eledon Pharmaceuticals \/ Eledon Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Eledon Pharmaceuticals \/ Eledon Pharmaceuticals"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Tatsuo Kawai, MD, PhD","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Nephrology","graph2":"Phase I","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eledon Pharmaceuticals \/ Tatsuo Kawai, MD, PhD","highestDevelopmentStatusID":"6","companyTruncated":"Eledon Pharmaceuticals \/ Tatsuo Kawai, MD, PhD"}]
Find Clinical Drug Pipeline Developments & Deals by Eledon Pharmaceuticals
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
